Kala Bio Overview
- Year Founded
-
2009

- Status
-
Public
- Employees
-
43

- Stock Symbol
-
KALA

- Investments
-
1
- Share Price
-
$10.73
- (As of Thursday Closing)
Kala Bio General Information
Description
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
Contact Information
Website
www.kalarx.comCorporate Office
- 1167 Massachusetts Avenue
- Arlington, MA 02476
- United States
Corporate Office
- 1167 Massachusetts Avenue
- Arlington, MA 02476
- United States
Kala Bio Timeline
Kala Bio Stock Performance
As of 06-Feb-2025, Kala Bio’s stock price is $10.73. Its current market cap is $65.4M with 6.09M shares.
(As of Thursday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$10.73 | $9.70 | $4.21 - $10.79 | $65.4M | 6.09M | 48.2K | -$11.86 |
Kala Bio Financials Summary
As of 30-Sep-2024, Kala Bio has a trailing 12-month revenue of null.
In Thousands, USD |
TTM 30-Sep-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
---|---|---|---|---|
EV | 8,867 | (1,129) | 51,139 | 61,787 |
Revenue | 0 | 0 | 3,892 | 11,240 |
EBITDA | (35,032) | (38,793) | (37,683) | (133,354) |
Net Income | (38,963) | (42,199) | (44,822) | (142,605) |
Total Assets | 54,079 | 55,949 | 86,820 | 139,427 |
Total Debt | 37,039 | 36,323 | 42,950 | 80,188 |
Kala Bio Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Kala Bio Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
---|
Kala Bio Comparisons
Industry
Financing
Details
Kala Bio Competitors (28)
One of Kala Bio’s 28 competitors is Aldeyra Therapeutics, a Formerly VC-backed company based in Lexington, MA.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Aldeyra Therapeutics | Formerly VC-backed | Lexington, MA | ||||
PulseSight Therapeutics | Venture Capital-Backed | Paris, France | ||||
ONL Therapeutics | Venture Capital-Backed | Ann Arbor, MI | ||||
Exonate | Venture Capital-Backed | Cambridge, United Kingdom | ||||
Alnylam Pharmaceuticals | Formerly VC-backed | Cambridge, MA |
Kala Bio Signals
Kala Bio Acquisitions (1)
Kala Bio’s most recent deal was a Merger/Acquisition with Combangio for . The deal was made on 15-Nov-2021.
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
Combangio | 15-Nov-2021 | Merger/Acquisition | Drug Discovery |
Kala Bio ESG
Risk Overview
Risk Rating
Updated October, 04, 2022
35.77 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,638
Rank
Percentile

Pharmaceuticals
Industry
of 1,008
Rank
Percentile

Pharmaceuticals
Subindustry
of 473
Rank
Percentile

Kala Bio FAQs
-
When was Kala Bio founded?
Kala Bio was founded in 2009.
-
Where is Kala Bio headquartered?
Kala Bio is headquartered in Arlington, MA.
-
What is the size of Kala Bio?
Kala Bio has 43 total employees.
-
What industry is Kala Bio in?
Kala Bio’s primary industry is Biotechnology.
-
Is Kala Bio a private or public company?
Kala Bio is a Public company.
-
What is Kala Bio’s stock symbol?
The ticker symbol for Kala Bio is KALA.
-
What is the current stock price of Kala Bio?
As of 06-Feb-2025 the stock price of Kala Bio is $10.73.
-
What is the current market cap of Kala Bio?
The current market capitalization of Kala Bio is $65.4M.
-
Who are Kala Bio’s competitors?
Aldeyra Therapeutics, PulseSight Therapeutics, ONL Therapeutics, Exonate, and Alnylam Pharmaceuticals are some of the 28 competitors of Kala Bio.
-
What is Kala Bio’s annual earnings per share (EPS)?
Kala Bio’s EPS for 12 months was -$11.86.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »